title: Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward.
abstract: BACKGROUND
  Although its incidence has been steadily decreasing in Western countries, gastric cancer remains a leading cause of cancer deaths worldwide. The detection rate of early-stage cancers is improving; nevertheless, the majority of cases is still diagnosed at later stages with a poor prognosis. Furthermore, the results that can be achieved with surgery have reached a plateau of effectiveness.
  
  
  CONCLUSIONS
  Neoadjuvant chemotherapy was successfully introduced first in patients with non-curatively resectable disease. In the last decade, neoadjuvant chemotherapy has also been established in potentially curatively resectable cases and has become the state-of-the-art treatment. Esophagogastric junction (EGJ) tumors are not optimally treated with chemotherapy alone, and combined radiochemotherapy (RCT) seems to yield superior outcomes.
  
  
  CONCLUSIONS
  The use of neoadjuvant therapy has been successfully established in patients with curatively resectable disease. Neoadjuvant chemotherapy is now a cornerstone in the treatment of gastric cancer and cancer of the EGJ, although further work is needed in order to define the optimal combination regimen.
  
  
  CONCLUSIONS
  Neoadjuvant chemotherapy is currently the gold standard for the treatment of gastric cancer and cancer of the EGJ. Several independent studies have shown the benefits of using combination regimens that included cisplatin and 5-fluorouracil, though recently the use of the EOX (epirubicin, oxaliplatin and capecitabine) regimen has been widely accepted in this setting. Tumors of the EGJ benefit from neoadjuvant treatment with combined RCT. It should be noted that the optimal neoadjuvant regimen in EGJ tumors has not yet been defined, and the survival advantage of neoadjuvant RCT over neoadjuvant chemotherapy remains to be established in this patient population.
authors.affiliation: Department of Internal Medicine 2, Diakonie-Hospital, Schwäbisch Hall, Recklinghausen, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Menges
authors.affiliation: Department of Internal Medicine 1, Prosper Hospital, Recklinghausen, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hoehler
keywords: Cancer of the esophagogastric junction; Gastric cancer; Improvement of prognosis; Neoadjuvant chemotherapy; Neoadjuvant radiochemotherapy